Table 2 Clinical trials with mRNA vaccines against viral diseases
Infectious disease tpye/ Virus type | NCT number | Drug administration | Phase | Status |
|---|---|---|---|---|
SARS-CoV-2 | NCT04523571 | BNT162b1 + placebo | I | Recruiting |
NCT04449276 | CVnCoV Vaccine+placebo | I | Recruiting | |
NCT04470427 | mRNA-1273 + placebo | III | Recruiting | |
NCT04368728 | BNT162b1 + BNT162b2 | I/II/III | Recruiting | |
NCT04515147 | CVnCoV | IIA | Not yet recruiting | |
NCT04283461 | mRNA-1273 | I | Active, not recruiting | |
NCT04405076 | mRNA-1273 + placebo | IIA | Active, not recruiting | |
Rabies | NCT02241135 | CV7201 mRNA encoding the rabies virus glycoprotein | I | Completed |
NCT03713086 | Rabipur® | I | Active, not recruiting | |
HIV-1 Infection | NCT00833781 | mRNA-transfected autologous DCs+/− autologous DCs with no mRNA transfection | I/II | Completed |
NCT02413645 | TriMix mRNA+/−HIV mRNA | I | Completed | |
NCT02888756 | iHIVARNA-01 + TriMix+/−Placebo | IIA | Terminated | |
Zika Virus | NCT03014089 | mRNA-1325 + placebo | I | Completed |
NCT04064905 | mRNA-1893 + placebo | I | Active, not recruiting | |
Tuberculosis | NCT01669096 | GSK 692342 | II | Completed |
Human Metapneumovirus and Human Parainfluenza Infection | NCT03392389 | mRNA-1653 + placebo | I | Completed |
NCT04144348 | mRNA-1653 + placebo | Ib | Recruiting | |
Ebola Virus Disease | NCT02485912 | two separate mRNAs encoding two Zaire strain Ebola glycoproteins, respectively | I | Completed |
Influenza | NCT03076385 | VAL-506440 + placebo | I | Completed |
Respiratory Syncytial Virus | NCT04528719 | mRNA-1345 + placebo | I | Not yet recruiting |
Cytomegalovirus Infection | NCT03382405 | mRNA-1647, mRNA-1443 | I | Active, not recruiting |
NCT04232280 | mRNA-1647 + placebo | II | Active, not recruiting |